SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Welsh Amy

(Last)

(First)

(Middle)

500 COLLEGE ROAD EAST, SUITE 310

(Street)

PRINCETON,

08540

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/01/2022

3. Issuer Name and Ticker or Trading Symbol
AGILE THERAPEUTICS INC [ AGRX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Buy)	⁽¹⁾	04/27/2030	Common Stock	1,500	$95.6	D
Employee Stock Option (Right to Buy)	⁽²⁾	01/27/2031	Common Stock	1,000	$112.8	D
Employee Stock Option (Right to Buy)	⁽³⁾	01/19/2032	Common Stock	1,000	$13.68	D

Explanation of Responses:

1. This option was granted on April 27, 2020. 25% of the shares subject to the stock option vested on April 27, 2021, and the remaining shares vest in 36 equal monthly installments over the following three years, such that the option will be fully vested by April 27, 2024.

2. This option was granted on January 27, 2021. 25% of the shares subject to the stock option vested on January 27, 2022, and the remaining shares vest in 36 monthly installments over the following three years, such that the option will be fully vested by January 27, 2025.

3. This option was granted on January 19, 2022. 25% of the shares subject to the stock option vest on January 19, 2023, and the remaining shares vest in 36 equal monthly installments over the following three years, such that the option will be fully vested by January 19, 2026.

Remarks:

Exhibit List 24.1 - Power of Attorney

	/s/ Geoffrey P. Gilmore Attorney-in-Fact	11/09/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.